Benitec Biopharma Inc.
General ticker "BNTC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $578.7M (TTM average)
Benitec Biopharma Inc. follows the US Stock Market performance with the rate: 8.9%.
Estimated limits based on current volatility of 2.4%: low 12.53$, high 13.15$
Factors to consider:
- Total employees count: 19 (+18.8%) as of 2025
- Top business risk factors: Incur losses, Operational and conduct risks, Raise funding, Clinical trial failure, Manufacturing risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [6.94$, 16.87$]
- 2026-06-30 to 2027-06-30 estimated range: [4.96$, 12.79$]
Financial Metrics affecting the BNTC estimates:
- Positive: with PPE of -9.3 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term BNTC quotes
Long-term BNTC plot with estimates
Financial data
| YTD | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating Revenue | $0.07MM | $0.00MM | $0.00MM |
| Operating Expenses | $19.16MM | $22.49MM | $41.77MM |
| Operating Income | $-19.08MM | $-22.49MM | $-41.77MM |
| Non-Operating Income | $-0.48MM | $0.74MM | $3.85MM |
| R&D Expense | $12.77MM | $15.61MM | $18.33MM |
| Income(Loss) | $-19.56MM | $-21.75MM | $-37.92MM |
| Net Income(Loss)* | $-19.56MM | $-21.75MM | $-37.92MM |
| Stockholders Equity | $0.20MM | $47.25MM | $97.30MM |
| Assets | $4.46MM | $52.21MM | $99.59MM |
| Operating Cash Flow | $-18.01MM | $-19.40MM | $-23.59MM |
| Capital expenditure | $0.00MM | $0.18MM | $0.02MM |
| Investing Cash Flow | $-0.00MM | $-0.18MM | $-0.02MM |
| Financing Cash Flow | $16.02MM | $68.03MM | $70.48MM |
| Earnings Per Share** | $-14.12 | $-2.12 | $-1.05 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.